News

Under the terms of the agreement, ThioPharma will receive an upfront payment and milestone payments upon achievement of certain development and regulatory events. Cenomed has also agreed to

Enrollment was completed approximately one month ahead of schedule, with results from the study expected to be available by the third quarter of 2008. This study will evaluate

PS433540 is a dual-acting angiotensin and endothelin receptor antagonist that is being developed as a potential treatment for hypertension and diabetic nephropathy. Data demonstrated that PS433540 produced statistically

In this test, both uncoated and Cerashield coated tube segments were exposed to daily challenges of one million colony forming units per ml of Pseudomonas aeruginosa in nutrient

Accordingly, Ipsen and Erasmus Research Institute for Neuroendocrinology research teams will meet regularly to identify new therapeutic opportunities leading to novel pharmaceutical compounds, or the identification of novel

GeoPharma said that the only ovarian cancer diagnostic test is the CA-125 blood test that is approved by the FDA to monitor progression of the disease. For best

The candidate, AVI-4658, uses Avi’s exon skipping pre-RNA interference technology (ESPRIT) to potentially benefit Duchenne muscular dystrophy (DMD) patients who have mutations in exon 51 of the dystrophin

Neoprobe holds the exclusive rights to Lymphoseek under license from University of California, San Diego for use in diagnostic applications such as lymphatic mapping as well as in

The clinical trial is expected to enroll up to 50 patients in up to 12 centers throughout the US. The Phase II clinical trial is a three-sequence, open-label,